论文部分内容阅读
目的 :探讨多药耐药蛋白 (p170 )和多药耐药相关蛋白 (MRP)表达与初治急性白血病(AL)患者化疗效果的关系。方法 :用流式细胞仪检测 2 9例初治 AL患者骨髓单个核细胞中 p170和MRP蛋白表达。结果 :初治 AL患者 p170和 MRP蛋白表达率分别为 3 7.9%和 41.4% ;MRP蛋白阳性与阴性患者的首次完全缓解 (CR)差异无显著性 (P>0 .0 5 ) ;而 p170蛋白阳性与阴性患者的首次完全缓解 (CR)有显著性差异 (P<0 .0 5 ) ;p170和 MRP蛋白两者之间无相关性。结论 :作为预测初治AL 患者化疗效果的敏感性指标 ,p170明显优于 MRP蛋白
Objective: To investigate the relationship between the expression of multidrug resistance protein (p170), multidrug resistance-related protein (MRP) and chemotherapy in newly diagnosed acute leukemia (AL). Methods: Flow cytometry was used to detect the expression of p170 and MRP in bone marrow mononuclear cells from 29 AL patients. Results: The expression rates of p170 and MRP in newly diagnosed AL patients were 39.9% and 41.4%, respectively. There was no significant difference in the first complete remission (CR) between MRP positive and negative patients (P> 0.05) There was a significant difference in the first complete remission (CR) between positive and negative patients (P <0.05); there was no correlation between p170 and MRP proteins. CONCLUSIONS: p170 is significantly better than MRP protein as a predictor of chemosensitivity to newly diagnosed AL patients